View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Hybridan Team
  • Hybridan Team

Hybridan Small Cap Feast: 22 October 2025

22nd October 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential** Initial ...

Hybridan Team
  • Hybridan Team

Hybridan Small Cap Feast: 24/09/2025

Our daily digest of news from UK Small Caps 24th September 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: None Delistings: ...

Martijn Den Drijver
  • Martijn Den Drijver
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
 PRESS RELEASE

GENFIT Reports First-Half 2025 Financial Results and Provides Corpora...

GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May 2025 (received in July 2025) upon pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European countries€33.5 million in revenues, including the €26.5 million milestone invoiced in May 2025Strong 1H25 sales trajectory reported by Ipsen for Iqirvo® in PBC in July, followed by U.S. market exit of key competitor in SeptemberFollowing discontinuation of the VS-01 program...

 PRESS RELEASE

GENFIT : Résultats financiers du premier semestre 2025 et point sur le...

GENFIT : Résultats financiers du premier semestre 2025 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant à 107,5 millions d’euros au 30 juin 2025 n’incluant pas le paiement d’étape de 26,5 millions d’euros facturé en mai 2025 (reçu en juillet 2025) à la suite de l'approbation par trois pays européens majeurs du prix et du remboursement d'Iqirvo® (elafibranor).33,5 millions d'euros de revenus, dont 26,5 millions d'euros de paiement d'étape facturé en mai 2025.Forte croissance des ventes d'Iqirvo® dans la PBC au premier semestre 2025 annoncée par Ipse...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch